KRAS ligand 3, identified by its CAS number 2654741-53-2, is a small molecule that acts as a selective inhibitor of the KRAS protein, which is a critical component in cell signaling pathways that regulate cell growth and division. This compound is particularly significant in cancer research, as mutations in the KRAS gene are commonly associated with various types of cancers, including pancreatic, colorectal, and lung cancers. The characteristics of KRAS ligand 3 include its ability to bind specifically to the mutant forms of KRAS, thereby inhibiting its activity and potentially leading to reduced tumor growth. The compound's structure typically features functional groups that enhance its binding affinity and specificity for the KRAS protein. Additionally, its pharmacokinetic properties, such as solubility, stability, and bioavailability, are crucial for its effectiveness as a therapeutic agent. Ongoing research aims to further elucidate its mechanism of action and therapeutic potential in oncology.

KRAS ligand 3

2654741-53-2: KRAS ligand 3, identified by its CAS number 2654741-53-2, is a small molecule that acts as a selective inhibitor of the KRAS protein, which is a critical component in cell signaling pathways that regulate cell growth and division. This compound is particularly significant in cancer research, as mutations in the KRAS gene are commonly associated with various types of cancers, including pancreatic, colorectal, and lung cancers. The characteristics of KRAS ligand 3 include its ability to bind specifically to the mutant forms of KRAS, thereby inhibiting its activity and potentially leading to reduced tumor growth. The compound's structure typically features functional groups that enhance its binding affinity and specificity for the KRAS protein. Additionally, its pharmacokinetic properties, such as solubility, stability, and bioavailability, are crucial for its effectiveness as a therapeutic agent. Ongoing research aims to further elucidate its mechanism of action and therapeutic potential in oncology.

<p>KRAS ligand 3 (compound 1), a BTX-6654 target-binding ligand, exhibits synergistic tumor growth inhibition through its capacity to bind a KRAS inhibitor [1].</p>

CAS 2654741-53-2

KRAS ligand 3

KRAS ligand 3

Ref: TM-T86787